东莨菪碱市场：按配方、分销渠道、地区 - 规模、份额、前景、机会分析，2022-2030

东莨菪碱是一种从紫荆属植物中提取的生物碱药物，用于治疗噁心和晕动病，以及在眼科手术中扩张瞳孔。东莨菪碱属于一类称为抗胆碱能药的药物。东莨菪碱是一种从茄科植物中分离出来的托烷类生物碱，与阿托品和莨菪碱一样，在结构上模仿天然神经递质乙□胆碱。该药通过抑制神经递质乙□胆碱的活性，刺激大脑中引起噁心和呕吐、肺部、胃肠道和泌尿道等肌肉不自主运动的部位，并发挥其作用。东莨菪碱在医疗环境中用作镇静剂和催眠剂，有时与吗啡一起缓解疼痛。东莨菪碱也被规定为“标籤外”，以缓解与抑郁症、哮喘、戒烟辅助和化疗相关的噁心。美国国家生物技术信息中心2019年7月公布的数据显示，东莨菪碱是一种抗胆碱能颠茄生物碱，通过竞争性抑制毒蕈碱受体影响副交感神经功能，对乙□胆碱有反应，但对胆碱无反应，作用于非受神经支配的平滑肌。东莨菪碱是一种贴剂配方，可持续释放 3 天，并且在尿液中可检测到 108 小时。东莨菪碱在闭角型青光眼中是禁忌的，由于其升高眼压的作用，开角型青光眼患者必须谨慎使用。

市场动态

全球患有压力和焦虑症的人口不断增长，预计将推动全球东莨菪碱市场的增长。例如，2022年3月，GOQii印度压力与心理健康调查公布的数据显示，2021年有29.31%的印度人患有抑郁症。 10个患有胃肠道疼痛的人中有7个将其归因于压力。根据美国国家生物技术信息中心的数据，美国约有 12% 的成年人患有肠易激综合征，原因是在 COVID-19 大流行造成经济损失后压力增加。女性患肠易激综合征的可能性是男性的两倍。多达四分之三的肠易激综合征患者将压力作为可靠来源。神经系统控制肠道并对心理压力作出反应。

本研究的主要特点

• 本报告对全球东莨菪碱市场进行了深入分析，提供了以 2021 年为基准年的预测期（2022-2030 年）的市场规模和復合年增长率 (CAGR%)。
• 解释不同细分市场的潜在收入机会，并描述该市场具有吸引力的投资建议矩阵。
• 该研究还提供了有关市场驱动因素、抑制因素、机会、新产品发布或批准、市场趋势、区域前景以及主要参与者采用的竞争策略的重要见解。
• 它根据以下参数描述了全球东莨菪碱市场的主要参与者 - 公司亮点、产品组合、关键亮点、财务业绩和战略
• 本研究涵盖的主要公司包括 Baxter International Inc.、GlaxoSmithKline plc. Novartis AG、Perrigo Company plc.、Caleb Pharmaceuticals, Inc.、Myungmoon Pharma Co. LTD.、Alchem International、Phytex Australia、Centroflora -Cms、澳大利亚生物碱和精细化工公司
• 本报告中的见解将使营销人员和企业高管能够就其未来的产品发布、类型升级、市场扩张和营销策略做出明智的决策。可能
• 全球东莨菪碱市场报告面向行业内的各种利益相关者，包括投资者和供应商、产品製造商、分销商、新进入者和金融分析师。
• 利益相关者可以通过在分析全球东莨菪碱市场时使用的各种策略矩阵轻鬆做出决策。

内容

第 1 章目的和先决条件

• 调查目的
• 先决条件
• 缩写说明

第2章市场展望

• 举报内容
  • 市场定义和范围
• 执行摘要
  • 市场快照：按剂型
  • 市场快照：按分销渠道
  • 市场概况：按地区划分
• 连贯的机会图 (COM)

第 3 章市场动态、法规和趋势分析

• 市场动态
  • 驱动程序
  • 约束因素
  • 市场机会
• 影响分析
• 市场趋势
• 主要发展状况
• 流行病学
• 历史概览
• 药品的盈利潜力
• 搬运工五力
• PEST 分析

第 4 章东莨菪碱全球市场 - 冠状病毒 (COVID-19) 大流行的影响

• 整体影响
• 政府举措
• COVID-19 对市场的影响

第 5 章全球东莨菪碱市场，按配方，2017-2030 年

• 药片
• 糖浆
• 注入
• 补丁
• 其他

第 6 章全球东莨菪碱市场，按分销渠道，2017-2030 年

• 医院药房
• 零售药房
• 在线药店

第 7 章。2017-2030 年东莨菪碱全球市场，按地区分列

• 北美
• 美国
• 加拿大
• 拉丁美洲
• 巴西
• 墨西哥
• 阿根廷
• 其他拉丁美洲地区
• 欧洲
• 英国
• 德国
• 意大利
• 法国
• 西班牙
• 俄罗斯
• 其他欧洲
• 亚太地区
• 中国
• 印度
• 日本
• 东盟
• 澳大利亚
• 韩国
• 其他亚太地区
• 中东
• 海合会
• 以色列
• 其他中东地区
• 非洲
• 北非
• 中非
• 南非

第 8 章竞争格局

• 热图分析
• 公司简介
  • Baxter International Inc.
  • GlaxoSmithKline plc
  • Novartis AG
  • Perrigo Company plc.
  • Caleb Pharmaceuticals, Inc.
  • Myungmoon Pharma Co. LTD.
  • Alchem International
  • Phytex Australia
  • Centroflora-Cms
  • Alkaloids of Australia
  • Fine Chemicals Corporation

第9章 章节

• 参考文献
• 调查手法

Scopolamine is an alkaloid drug extracted from a plant called henbane to treat nausea and motion sickness and further to dilate the pupil in ophthalmic procedures. Scopolamine belongs to a class of drugs called anticholinergic. Scopolamine is a tropane alkaloid isolated from members of the Solanaceae family of plants, similar to atropine and hyoscyamine, all of which structurally mimic the natural neurotransmitter acetylcholine. It works by blocking the activity of the neurotransmitter acetylcholine, which stimulates the part of the brain that triggers nausea and vomiting, involuntary muscle movement in the lungs, and the gastrointestinal and urinary tracts. Scopolamine is also used in medicine as a sedative or hypnotic and sometimes with morphine to relieve pain. Scopolamine has also been prescribed 'off label' for depression, asthma, as a smoking-cessation remedy, and to relieve the nausea that accompanies chemotherapy. According to data published by National Center for Biotechnology Information, in July 2019, Scopolamine is an anticholinergic belladonna alkaloid that, through competitive inhibition of muscarinic receptors, affects parasympathetic nervous system function and acts on smooth muscles that respond to acetylcholine but lack cholinergic innervation. Formulated as a patch, scopolamine is released continuously over three days and remains detectable in urine over a period of 108 hours. Scopolamine is contraindicated in angle-closure glaucoma and should be used with caution in patients with open-angle glaucoma due to scopolamine's ability to increase intraocular pressure.

Market Dynamics

Increasing global population suffering from stress and anxiety disorders is expected to fuel growth of the global scopolamine market. For instance, in March 2022, according to data published by the GOQii survey on the stress and mental health status of Indians, the GOQii Survey indicates that 29.31% of Indians were suffering from depression in 2021. Stress was the cause for seven out of ten patients suffering from gastrointestinal pain. According to the National Center for the Biotechnology Information around 12 percent Trusted Source of adults in the United States have Irritable bowel syndrome due to increasing stress after economic loss in covid-19 pandemic. Women are twice as likely to have Irritable bowel syndrome as men. As many as three-quarters Trusted Source of people with Irritable bowel syndrome report stress. The nervous system controls the gut and also responds to psychological stress.

Key features of the study:

• This report provides an in-depth analysis of the global scopolamine market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global scopolamine market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Baxter International Inc., GlaxoSmithKline plc. Novartis AG, Perrigo Company plc., Caleb Pharmaceuticals, Inc., Myungmoon Pharma Co. LTD., Alchem International, Phytex Australia, Centroflora-Cms, Alkaloids of Australia, and Fine Chemicals Corporation
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global scopolamine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global scopolamine market

Detailed Segmentation:

• Global Scopolamine Market, By Dosage Form:
  • Tablet
  • Syrup
  • Injection
  • Patch
  • Others
• Global Scopolamine Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Scopolamine Market, By Region:
  • North America
    • By Country
  • U.S.
  • Canada
  • Latin America
    • By Country
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • By Country
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • By Country
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
    • By Country
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • By Region/Country
  • South Africa
  • Central Africa
  • North Africa
• Company Profiles
  • Baxter International Inc.*
    • Company Highlights
    • Products Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • GlaxoSmithKline plc
  • Novartis AG
  • Perrigo Company plc.
  • Caleb Pharmaceuticals, Inc.
  • Myungmoon Pharma Co. LTD.
  • Alchem International
  • Phytex Australia
  • Centroflora-Cms
  • Alkaloids of Australia
  • Fine Chemicals Corporation

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Dosage Form
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Market Trends
• Key Developments
• Epidemiology
• Historical Overview
• Revenue Potential of Drugs
• PORTER'S Five Forces
• PEST Analysis

4. Global Scopolamine Market - Impact of Coronavirus (Covid-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the market

5. Global Scopolamine Market, By Dosage Form, 2017 - 2030, (US$ Million)

• Overview
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Tablet
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Syrup
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Injection
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Patch
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

6. Global Scopolamine Market, By Distribution Channel, 2017 - 2030, (US$ Million)

• Overview
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Hospital Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Retail Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Online Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

7. Global Scopolamine Market, By Region, 2017 - 2030, (US$ Million)

• Introduction
  • Market Share Analysis, By Region, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, For Regions, 2017-2030
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• U.S.
• Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• UK
• Germany
• Italy
• France
• Spain
• Russia
• Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• China
• India
• Japan
• ASEAN
• Australia
• South Korea
• Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• GCC
• Israel
• Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017 - 2030, (US$ Million)
• North Africa
• Central Africa
• South Africa

8. Competitive Landscape

• Heat Map Analysis
• Company Profiles
  • Baxter International Inc.
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Market Market Strategies
  • GlaxoSmithKline plc
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Market Market Strategies
  • Novartis AG
• Company Overview
• Dosage Form Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • Perrigo Company plc.
• Company Overview
• Dosage Form Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • Caleb Pharmaceuticals, Inc.
• Company Overview
• Dosage Form Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • Myungmoon Pharma Co. LTD.
• Company Overview
• Dosage Form Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • Alchem International
• Company Overview
• Dosage Form Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • Phytex Australia
• Company Overview
• Dosage Form Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • Centroflora-Cms
• Company Overview
• Dosage Form Portfolio
• Financial Performance
• Recent Highlights
  • Alkaloids of Australia
• Company Overview
• Dosage Form Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • Fine Chemicals Corporation
• Company Overview
• Dosage Form Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies

9. Section

• References
• Research Methodology
• About Us and Sales Contact